Literature DB >> 718472

Peripheral neuropathy in myotonic dystrophy. Relation to glucose intolerance.

N D Olson, M F Jou, J E Quast, F Q Nuttall.   

Abstract

Motor nerve conduction velocity (MNCV) was measured in three peripheral nerves in each of 24 patients with myotonic dystrophy having various degress of associated glucose intolerance and was compared with results in a control group. Both groups had similar glucose tolerance and were matched for age and adiposity. The mean MNCV in the ulnar, median, and peroneal nerves in the myotonic dystrophy group were all significantly slowed (P less than .01). This peripheral nerve dysfunction, usually subclinical, is yet another manifestation of this multisystem disease and is unrelated to the associated glucose intolerance.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 718472     DOI: 10.1001/archneur.1978.00500350045009

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  5 in total

1.  Skeletal muscle changes associated with equine myotonic dystrophy.

Authors:  G A Hegreberg; S M Reed
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  Short-latency somatosensory evoked potentials in dystrophia myotonica.

Authors:  P R Bartel; B P Lotz; C H Van der Meyden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-05       Impact factor: 10.154

3.  Measurement of motor conduction velocity with Hopf's technique in myotonic dystrophy.

Authors:  B Rossi; F Sartucci; A Stefanini; G Pucci; F Bianchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-01       Impact factor: 10.154

4.  Peripheral nerve axon involvement in myotonic dystrophy type 1, measured using the automated nerve excitability test.

Authors:  Jong Seok Bae; Sang Gin Kim; Jeong Cheol Lim; Eun Joo Chung; Oeung Kyu Kim
Journal:  J Clin Neurol       Date:  2011-06-28       Impact factor: 3.077

5.  Association of peripheral neuropathy with sleep-related breathing disorders in myotonic dystrophies.

Authors:  Marta Banach; Jakub Antczak; Rafał Rola
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-12       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.